0 -5.24400024668755E-06 -4.62705904116395E-06 -0.000925411808254708 -4.68875316182152E-05 -0.000154235301375814 -0.000123388241100686 -0.000123388241100686
Sign Up Today X
Thanks for submitting the form.
Stockreport

Amgen CEO says weight loss drug can address ‘patient persistence issue' [CNBC]

Amgen Inc. (AMGN)  More Company Research Source: CNBC
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
“We think we can address one of the reasons that the field is struggling a little bit, which is the patient persistence issue,” Bradway said. Amgen CEO Bob Bradway told CNBC's Jim Cramer he thinks his company's obesity drug can help patients manage weight loss long term, which he indicated is a challenge. “We think we can address one of the reasons that the field is struggling a little bit, which is the patient persistence issue,” Bradway said. Amgen revealed Monday that a trial of its experimental GLP-1 drug, MariTide, showed that patients were able to maintain weight loss for two years when given a monthly injection. Right now, most widely-used weight loss injections are taken weekly. Bradway told Cramer that the pharmaceutical giant expects the drug can be used monthly or even less frequently, saying he's encouraged about data that suggests it can be taken quarterly. Bradway also said Amgen is studying the efficacy of a range of different doses, adding that “we want to und [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

Amgen CEO says weight loss drug can address ‘patient persistence issue' [CNBC]

Amgen Inc.  (AMGN) 
More Company Research Source: CNBC
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
“We think we can address one of the reasons that the field is struggling a little bit, which is the patient persistence issue,” Bradway said. Amgen CEO Bob Bradway told CNBC's Jim Cramer he thinks his company's obesity drug can help patients manage weight loss long term, which he indicated is a challenge. “We think we can address one of the reasons that the field is struggling a little bit, which is the patient persistence issue,” Bradway said. Amgen revealed Monday that a trial of its experimental GLP-1 drug, MariTide, showed that patients were able to maintain weight loss for two years when given a monthly injection. Right now, most widely-used weight loss injections are taken weekly. Bradway told Cramer that the pharmaceutical giant expects the drug can be used monthly or even less frequently, saying he's encouraged about data that suggests it can be taken quarterly. Bradway also said Amgen is studying the efficacy of a range of different doses, adding that “we want to und [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS